Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SHEPHERD: Safety in Hemolytic PNH Patients Treated With Eculizumab: A Multi-Center Open-Label Research Design

NCT00130000 is registered in ClinicalTrials.gov with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor.

NCT NCT00130000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00130000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SHEPHERD: Safety in Hemolytic PNH Patients Treated With Eculizumab: A Multi-Center Open-Label Research Design
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Phase
Phase 3
Overall status
Completed
Start date
August 9, 2005
Completion date
June 25, 2007
Enrollment
87
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal hemoglobinuria, nocturnal